Antibody-dependent enhancement of Marburg virus infection.

BACKGROUND Marburg virus (MARV) and Ebola virus (EBOV) cause severe hemorrhagic fever in primates. Earlier studies demonstrated that antibodies to particular epitopes on the glycoprotein (GP) of EBOV enhanced virus infectivity in vitro. METHODS To investigate this antibody-dependent enhancement (ADE) in MARV infection, we produced mouse antisera and monoclonal antibodies (mAbs) to the GPs of MARV strains Angola and Musoke. RESULTS The infectivity of vesicular stomatitis virus pseudotyped with Angola GP in K562 cells was significantly enhanced in the presence of Angola GP antisera, whereas only minimal ADE activity was seen with Musoke GP antisera. This difference correlated with the percentage of hybridoma clones producing infectivity-enhancing mAbs. Using mAbs to MARV GP, we identified 3 distinct ADE epitopes in the mucinlike region on Angola GP. Interestingly, some of these antibodies bound to both Angola and Musoke GPs but showed significantly higher ADE activity for strain Angola. ADE activity depended on epitopes in the mucinlike region and glycine at amino acid position 547, present in the Angola but absent in the Musoke GP. CONCLUSIONS These results suggest a possible link between ADE and MARV pathogenicity and provide new insights into the mechanisms underlying ADE entry of filoviruses.

[1]  Kimihito Ito,et al.  Enzyme-Linked Immunosorbent Assay for Detection of Filovirus Species-Specific Antibodies , 2010, Clinical and Vaccine Immunology.

[2]  Y. Kawaoka,et al.  Different Potential of C-Type Lectin-Mediated Entry between Marburg Virus Strains , 2010, Journal of Virology.

[3]  Kathryn L. Schornberg,et al.  The Primed Ebolavirus Glycoprotein (19-Kilodalton GP1,2): Sequence and Residues Critical for Host Cell Binding , 2009, Journal of Virology.

[4]  Y. Kawaoka,et al.  Epitopes required for antibody-dependent enhancement of Ebola virus infection. , 2007, The Journal of infectious diseases.

[5]  P. Formenty,et al.  Marburg Virus Angola Infection of Rhesus Macaques: Pathogenesis and Treatment with Recombinant Nematode Anticoagulant Protein c2 , 2007, The Journal of infectious diseases.

[6]  X. Qiu,et al.  Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. , 2007, Journal of virological methods.

[7]  V. Volchkov,et al.  Characterization of Marburg virus glycoprotein in viral entry. , 2007, Virology.

[8]  H. Feldmann,et al.  Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine , 2006, Journal of Virology.

[9]  Alan Kemp,et al.  Marburg hemorrhagic fever associated with multiple genetic lineages of virus. , 2006, The New England journal of medicine.

[10]  J. A. Comer,et al.  Marburgvirus Genomics and Association with a Large Hemorrhagic Fever Outbreak in Angola , 2006, Journal of Virology.

[11]  J. Kuhn,et al.  Conserved Receptor-binding Domains of Lake Victoria Marburgvirus and Zaire Ebolavirus Bind a Common Receptor* , 2006, Journal of Biological Chemistry.

[12]  L. Fernando,et al.  Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment , 2006, The Lancet.

[13]  M. Aman,et al.  Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. , 2004, FEMS immunology and medical microbiology.

[14]  C. Roth,et al.  Risk Factors for Marburg Hemorrhagic Fever, Democratic Republic of the Congo , 2003, Emerging infectious diseases.

[15]  Y. Kawaoka,et al.  Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications , 2003, Reviews in medical virology.

[16]  Y. Kawaoka,et al.  Antibody-Dependent Enhancement of Ebola Virus Infection , 2003, Journal of Virology.

[17]  Emiko Suzuki,et al.  Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP , 2002, Journal of Virology.

[18]  Shinji Watanabe,et al.  Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein , 2001, Journal of Virology.

[19]  E. Nabel,et al.  Yang, Z.-Y. et al. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6, 886-889 , 2000 .

[20]  S. Hazar,et al.  Filoviridae: Marburg and Ebola viruses. , 2000 .

[21]  E. Nabel,et al.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury , 2000, Nature Medicine.

[22]  A. Sanchez,et al.  Mutational Analysis of the Putative Fusion Domain of Ebola Virus Glycoprotein , 1999, Journal of Virology.

[23]  J. McCormick,et al.  Experimental filovirus infections. , 1999, Current topics in microbiology and immunology.

[24]  A. Sanchez,et al.  Variation in the Glycoprotein and VP35 Genes of Marburg Virus Strains☆ , 1998, Virology.

[25]  A. Sanchez,et al.  A system for functional analysis of Ebola virus glycoprotein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Sanchez,et al.  The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Jahrling,et al.  Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. , 1996, Archives of virology. Supplementum.

[28]  Update: filovirus infection in animal handlers. , 1990, MMWR. Morbidity and mortality weekly report.

[29]  K. Johnson,et al.  MARBURG-VIRUS DISEASE IN KENYA , 1982, The Lancet.

[30]  R. Salt,et al.  PERCUTANEOUS LUNG BIOPSY , 1976, The Lancet.

[31]  T. Bothwell,et al.  Outbreake of Marburg virus disease in Johannesburg. , 1975, British medical journal.

[32]  J. Casals,et al.  Marburg Virus Disease , 1972, The Yale Journal of Biology and Medicine.